Medgenics Wins Patent for Core Technology Used in Sustained Delivery of Erythropoietin
Medgenics, Inc. (NYSE: MDGN), the developer of Biopump^TM a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced a patent granted by the U.S. Patent and Trademark Office (USPTO) protecting the use of Medgenics' EPODURE Biopump technology for delivery of erythropoietin (EPO). Medgenics is developing EPODURE to address the need for safer, sustained treatment of anemia. The USPTO also allowed claims covering a similar method for delivery of clotting Factor VIII, underlying Medgenics' HEMODURE™ Biopump technology for sustained prophylactic treatment of hemophilia.
Similar claims covering EPODURE and HEMODURE have also been recently allowed in Japan, China, Korea and Australia.
In total, Medgenics' global portfolio now includes 36 patents issued, with 81 more pending.
Medgenics believes its approach to protein therapy has multiple benefits compared with current treatments, which include regular and costly injections of therapeutic proteins. Medgenics' technologies target the global protein therapy market which is forecast to reach $132 billion in 2013.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.